Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 3
1987 1
1988 1
1990 1
1992 1
1993 2
1997 1
1998 1
1999 1
2000 2
2001 4
2002 13
2003 7
2004 11
2005 12
2006 18
2007 15
2008 15
2009 19
2010 16
2011 7
2012 8
2013 5
2014 3
2015 3
2016 2
2017 6
2018 2
2019 1
2020 3
2021 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Particle aggregation.
Burd AB, Jackson GA. Burd AB, et al. Ann Rev Mar Sci. 2009;1:65-90. doi: 10.1146/annurev.marine.010908.163904. Ann Rev Mar Sci. 2009. PMID: 21141030 Review.
Face.
Burd A. Burd A. J Plast Reconstr Aesthet Surg. 2007;60(11):1173-4. doi: 10.1016/j.bjps.2007.09.010. J Plast Reconstr Aesthet Surg. 2007. PMID: 17950183 No abstract available.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Duong VH, et al. Among authors: burd a. Cancer. 2023 Aug 1;129(15):2308-2320. doi: 10.1002/cncr.34780. Epub 2023 Apr 20. Cancer. 2023. PMID: 37078412 Clinical Trial.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. Cai SF, et al. Among authors: burd a. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. Blood Adv. 2024. PMID: 37871309 Free PMC article.
New skin.
Burd A. Burd A. Transplantation. 2000 Dec 15;70(11):1551-2. doi: 10.1097/00007890-200012150-00001. Transplantation. 2000. PMID: 11152212 No abstract available.
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
Lyu J, Liu Y, Gong L, Chen M, Madanat YF, Zhang Y, Cai F, Gu Z, Cao H, Kaphle P, Kim YJ, Kalkan FN, Stephens H, Dickerson KE, Ni M, Chen W, Patel P, Mims AS, Borate U, Burd A, Cai SF, Yin CC, You MJ, Chung SS, Collins RH, DeBerardinis RJ, Liu X, Xu J. Lyu J, et al. Among authors: burd a. Cancer Discov. 2023 Jan 9;13(1):170-193. doi: 10.1158/2159-8290.CD-21-1661. Cancer Discov. 2023. PMID: 36222845 Free PMC article.
Déjà Vu: Surgery and SARS.
Burd A. Burd A. Indian J Plast Surg. 2020 Mar;53(1):6-11. doi: 10.1055/s-0040-1709952. Epub 2020 Apr 22. Indian J Plast Surg. 2020. PMID: 32367911 Free PMC article. No abstract available.
Keratinocyte-keloid interaction.
Burd A, Chan E. Burd A, et al. Plast Reconstr Surg. 2002 Jul;110(1):197-202. doi: 10.1097/00006534-200207000-00033. Plast Reconstr Surg. 2002. PMID: 12087253 No abstract available.
Decompression not escharotomy in acute burns.
Burd A, Noronha FV, Ahmed K, Chan JY, Ayyappan T, Ying SY, Pang P. Burd A, et al. Burns. 2006 May;32(3):284-92. doi: 10.1016/j.burns.2005.11.017. Epub 2006 Mar 9. Burns. 2006. PMID: 16527416 Review.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Saliba AN, et al. Among authors: burd a. Blood Adv. 2023 Jun 13;7(11):2360-2363. doi: 10.1182/bloodadvances.2022008625. Blood Adv. 2023. PMID: 36315007 Free PMC article. Clinical Trial. No abstract available.
183 results